Search Results

You are looking at 241 - 250 of 529 items for :

  • "Adjuvant therapy" x
  • Refine by Access: All x
Clear All
Full access

Hepatobiliary Cancers, Version 2.2014

Al B. Benson III, Michael I. D’Angelica, Thomas A. Abrams, Chandrakanth Are, P. Mark Bloomston, Daniel T. Chang, Bryan M. Clary, Anne M. Covey, William D. Ensminger, Renuka Iyer, R. Kate Kelley, David Linehan, Mokenge P. Malafa, Steven G. Meranze, James O. Park, Timothy Pawlik, James A. Posey, Courtney Scaife, Tracey Schefter, Elin R. Sigurdson, G. Gary Tian, Jean-Nicolas Vauthey, Alan P. Venook, Yun Yen, Andrew X. Zhu, Karin G. Hoffmann, Nicole R. McMillian, and Hema Sundar

Cancers Local recurrence after surgery is a primary limitation for cure in patients with biliary tract cancers, which provides an important justification for the use of adjuvant therapy. Nevertheless, the role of adjuvant chemotherapy or chemoradiation

Full access

Controversies in Radiation for Upper Rectal Cancers

Emily Chan, Paul E. Wise, and A. Bapsi Chakravarthy

excision and no adjuvant therapy . J Gastrointest Surg 1999 ; 3 : 642 – 647 . 16 Guillem JG Diaz-Gonzalez JA Minsky BD . cT3N0 rectal cancer: potential overtreatment with preoperative chemoradiotherapy is warranted . J Clin Oncol 2008 ; 26

Full access

Testicular Cancer, Version 2.2015

Robert J. Motzer, Eric Jonasch, Neeraj Agarwal, Clair Beard, Sam Bhayani, Graeme B. Bolger, Sam S. Chang, Toni K. Choueiri, Brian A. Costello, Ithaar H. Derweesh, Shilpa Gupta, Steven L. Hancock, Jenny J. Kim, Timothy M. Kuzel, Elaine T. Lam, Clayton Lau, Ellis G. Levine, Daniel W. Lin, M. Dror Michaelson, Thomas Olencki, Roberto Pili, Elizabeth R. Plimack, Edward N. Rampersaud, Bruce G. Redman, Charles J. Ryan, Joel Sheinfeld, Brian Shuch, Kanishka Sircar, Brad Somer, Richard B. Wilder, Mary Dwyer, and Rashmi Kumar

these with patients and families and pick the best approach on a case-by-case basis. Adjuvant Therapy: Oliver et al 35 reported on the results of a trial that randomized 1477 patients with stage 1 testicular cancer to undergo either radiotherapy or

Full access

Calcium and Magnesium Use for Oxaliplatin-Induced Neuropathy: A Case Study to Assess How Quickly Evidence Translates Into Practice

Deirdre R. Pachman, Kathryn Ruddy, Lindsey R. Sangaralingham, Axel Grothey, Nilay D. Shah, Andreas S. Beutler, Joleen M. Hubbard, and Charles L. Loprinzi

across the world, including an adjuvant therapy trial (N04C7) that had accrued approximately 100 patients. However, a subsequent review of the data monitoring committee report showed that it was aberrant, and a subsequent Letter to the Editor in JCO

Full access

Delivery of Adjuvant Oxaliplatin for Colon Cancer: Insights From Routine Clinical Practice

Natasha Satkunam, Xuejiao Wei, James J. Biagi, Sulaiman Nanji, and Christopher M. Booth

. References 1. NIH consensus conference . Adjuvant therapy for patients with colon and rectal cancer . JAMA 1990 ; 264 : 1444 – 1450 . 2. IMPACT Investigators . Efficacy of adjuvant fluorouracil and folinic acid in colon cancer

Full access

Pathologic Complete Response After Neoadjuvant Chemotherapy and Long-Term Outcomes Among Young Women With Breast Cancer

Laura Spring, Rachel Greenup, Andrzej Niemierko, Lidia Schapira, Stephanie Haddad, Rachel Jimenez, Suzanne Coopey, Alphonse Taghian, Kevin S. Hughes, Steven J. Isakoff, Leif W. Ellisen, Barbara L. Smith, Michelle Specht, Beverly Moy, and Aditya Bardia

counterparts, which might be due to aggressive tumor biology and lower efficacy of adjuvant therapy, including endocrine therapy for HR-positive breast cancer in young women. For example, among patients with HR-positive disease, there are data in a Korean

Full access

Interdigitating Dendritic Cell Sarcoma

Venkata K. Pokuri, Mihai Merzianu, Shipra Gandhi, Junaid Baqai, Thom R. Loree, and Seema Bhat

poor predictors of outcome. The role of adjuvant therapy remains unclear. Chemotherapy options for metastatic disease are controversial. The authors have disclosed that they have no financial interests, arrangements, affiliations, or

Full access

VATS Versus Open Surgery for Lung Cancer Resection: Moving Beyond the Incision

Aaron M. Cheng and Douglas E. Wood

understaged may not receive the appropriate adjuvant therapy, and this is likely to result in survival differences now that adjuvant therapy has become standard of care for resected stage II or greater lung cancer. The NCCN Guidelines for Non–Small Cell Lung

Full access

Cutaneous Melanoma: Management of Melanoma Brain Metastases and Molecular Testing

Presented by: Douglas B. Johnson, Susan M. Swetter, April K.S. Salama, and Evan Wuthrick

number of unnecessary SLNBs, and inform decisions on imaging and adjuvant therapy, she explained, but there are still several unknowns. Nevertheless, experts estimate that up to 10% of all invasive melanomas are being GEP-tested with commercially

Full access

Neoadjuvant Immunotherapy–Based Systemic Treatment in MMR-Deficient or MSI-High Rectal Cancer: Case Series

Rahel Demisse, Neha Damle, Edward Kim, Jun Gong, Marwan Fakih, Cathy Eng, Leslie Oesterich, Madison McKenny, Jingran Ji, James Liu, Ryan Louie, Kit Tam, Sepideh Gholami, Wissam Halabi, Arta Monjazeb, Farshid Dayyani, and May Cho

fluorouracil-based adjuvant therapy in colon cancer . J Clin Oncol 2010 ; 28 : 3219 – 3226 . 20498393 10.1200/JCO.2009.27.1825 13. Salem ME , Hartley M , Unger K , . Neoadjuvant combined-modality therapy for locally advanced rectal cancer and its